Bionomics Limited to Participate in Upcoming November Investor Conferences
ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq:BNOX | ASX:BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in November:
Related news for (BNOX)
- 24/7 Market News Snapshot 08 November, 2024 – Bionomics Limited American Depository Shares (NASDAQ:BNOX)
- 24/7 Market News Snapshot 07 November, 2024 – Bionomics Limited American Depository Shares (NASDAQ:BNOX)
- Bionomics Receives AUS$1M Milestone Payment from Carina Biotech
- 24/7 Market News Snapshot 04 November, 2024 – Bionomics Limited American Depository Shares (NASDAQ:BNOX)
- Bionomics Reports Successful End-of-Phase 2 Meeting with the FDA for BNC210 in Post-Traumatic Stress Disorder